Intervertebral discs (IVD) degeneration, which is caused by ageing or mechanical stress, leads to IVD disease, including back pain and sciatica. The cytokine inter- The NP is comprised mainly of water, but also collagen fibrils, various proteoglycans for shock absorption and cells of the NP, which are adapted to survive in this hypoxic environment. [4] [5] [6] In degenerated IVD tissue, various inflammatory factors including interleukin (IL)-α/β, IL-2, IL-4, IL-6, IL-8, IL-10, nitric oxide, tumour necrosis factor α (TNF-α), matrix metalloproteinases (MMPs) and prostaglandin E 2 (PGE2) increase in the NP and stimulate-specific intracellular signalling pathways that further enhance this degenerative process [7] [8] [9] [10] [11] [12] 
through, for example, the degradation of collagen fibres and hydrophilic proteoglycans within the extracellular matrix(ECM). 13 PGE2 is synthesized by two cyclooxygenase (COX) isoforms, COX-1 and COX-2. 14 COX-2 expression is induced in response to inflammatory stimuli 15 and mechanical stress, and its expression initiates the degenerative cascade. 16 COX-2 and PGE-2 play key roles in lower back pain and sciatica. 7, 8, 17 As such, COX-2 is considered an important mediator of the IVD degenerative process 8 and is a therapeutic target for IVD disease. 8 Recently, IL-17 was reported to be increased in NP cells of degenerated or herniated IVDs, along with IL-4, IL-6, IL-12 and interferon-γ.
IL-17 is a cytokine produced by the T helper 17 subset of CD4 + T cells and plays critical roles in various inflammatory disorders. 18, 19 Its family is comprised of six members: IL-17A to IL-17F. 20 IL-17A binds to its cognate receptor (IL-17RA) and activates many intracellular signaling factors, including those of the nuclear factor kappa-light-chain-enhancer of activated B cells or mitogen-activated protein kinase (MAPK)
pathways. 21 IL-17A also synergistically increases the release of inflammatory mediators in disc cells. 22, 23 With respect to the relationship between IL-17A and other cytokines, IL-6 is one of a range of factors triggered when CD4 + T cells undergo differentiation into Th17 cells, which produce IL-17 in response to IL-6 and transforming growth factor β via Retinoic acid receptor-related Orphan Receptor (ROR)-γ. 24, 25 IL-17A also induces expression of IL-6 in fibroblasts 26 and triggers a positive feedback loop of IL-6 signalling. 27 In IVD disease and degeneration, IL-6 can potentiate the catabolic actions of other cytokines, including IL-1 and TNF-α, 28 induce apoptosis 29 and cause loss of IVD matrix proteins including MMP family members, such as MMP-3 or MMP-13. 28, 30 In addition, IL-6 and IL-6 receptor expression levels are responsive to IVD injury. 31 Thus, IL-6 plays an important role in the degenerative progression of NP cells and the various symptoms associated with degenerative disorders. Additionally, IL-17A may lead to an increase in COX-2 expression via the activation of MAPK pathways in disc degeneration. 32 Therefore, IL-17A may offer a potential target for therapeutic intervention for disc degeneration. However, there are few studies examining the role of IL-17 in disc cells. To address this, we focused on the crosstalk between IL-17A, IL-6 and COX-2 and investigated the effect of IL-17A on NP cells under hypoxic conditions (1% O 2 ), reflecting the in vivo context. The main objectives of this study were to examine the pharmacotherapeutic potential of IL-17A for the treatment of degenerative discs. We analysed the structure of IL-17A and the IL-17A receptor (IL-17RA) and identified small-molecule inhibitors that bind to the IL-17A-IL-17RA docking region and inhibit IL-17A signalling in NP cells. We evaluated the effects of these inhibitors as a potential new therapeutic strategy for disc diseases. 
| MATERIALS AND METHODS

| Human samples and histology
| Isolation of NP cells, cell treatments and hypoxic culture conditions
Rat NP cells were isolated from male Sprague-Dawley rats (11 weeks old) using a modified method previously reported by Risbud et al. 5 Briefly, IVDs from the lumbar and coccygeal regions were dissected from rats under deep anaesthesia using aseptic conditions. The gel- 
| Real-time RT-PCR analysis
Total RNA was extracted from NP cells using RNAeasy mini columns (Qiagen, Hilden, Germany). Before elution from the column, RNA was treated with RNase-free DNase I (Qiagen). The purified, DNAfree RNA was converted to cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems, Foster City, CA, USA).
Template cDNA and gene-specific primers were added to Power SYBR Green Master Mix (Applied Biosystems), and mRNA expression was quantified using the Step One Plus Real-time PCR System (Applied Biosystems). β-actin was used to normalize gene expression.
Melting curves were analysed to verify the specificity of the RT-PCR and the absence of primer dimer formation.
| Plasmids
The COX-2 promoter luciferase constructs phPES2-1432/+59 were kindly provided by Dr. Akihiko Hiyama (Tokai University, Kanagawa, Japan). 37 We used the vector pGL4.74 (Promega, Madison, WI, USA)
containing the Renilla reniformis luciferase gene as an internal transfection control.
| Transfections and dual-luciferase assay
Cells were transferred to 96-well plates (8 × Western Chemiluminescent HRP Substrate (Millipore) and scanned using an Ez-Capture MG imaging system (ATTO, Tokyo, Japan). The
Western blot data were quantified by densitometric scans of the films using computer software for Macintosh, CS analyzer (ATTO).
Western blot data are presented as band intensities normalized to that of the loading control (β-actin). 
| Alcian blue staining
| Colony-forming assay
To assess spheroid colony formation, single-cell suspensions of | 5541 dishes and cultured in 1 mL of MethoCult H4230 methylcellulose medium (Stem Cell Technologies) and were treated with 10-100 ng/ mL of IL-17A and 50-200 μg/mL of STK for 10 days. Colonies (>10 cells) were counted using an inverted microscope.
| Statistical analysis
All measurements were performed at least three times, and the data are presented as the mean ± standard deviations (SD). Differences between groups were analysed using Student's t test or one-way analyses of variance. Dunnett's test was used as post hoc test. Significance was set at P < 0.05.
| RESULTS
| Induction of IL-17A expression in NP cells of human herniated discs
We first classified the level of degeneration in IVD samples according to Pfirrmann's magnetic resonance classification 33 and considered IVD samples of grades III to V to be degenerative (Figure 1A) . Among our samples, six herniated disc samples were observed from patients with grade III or IV IVD, whereas samples from the five patients with idiopathic scoliosis were non-degenerated ( Figure 1A ,B).
To evaluate the involvement of IL-17A in IVD degeneration, Alcian blue staining was used to detect the sulphated glycosaminoglycans of NP cells on day 8, and we observed that IL-17A treatment lead to a significant decrease in sulphated glycosaminoglycans ( Figure 2E ).
| IL-6 increases COX-2 expression in primary NP Cells
Next, because IL-6 mRNA was prominently increased by IL-17A stimulation, we evaluated the effects of IL-6 in rat NP cells. Treatment with IL-6 led to a significantly increased expression of COX-2, MMP-3 and MMP-13 mRNA, like IL-17A treatment, but had no effect on IL-17A mRNA expression compared with untreated control cells ( Figure 2F ). In addition, we confirmed that COX-2 protein expression ( Figure 2G ,H) and COX-2 promoter transcriptional activity were significantly increased by IL-6 treatment compared with untreated control cells ( Figure 2I ). These results suggest that IL-6
induces expression of COX-2 and MMPs, but not IL-17A. Results shown as mean ± SD; n = 4, *P < 0.05. B, C, Western blot analysis of NP cells treated with 50 ng/mL IL-17A for 24 hours under hypoxic conditions. IL-17A treatment led to a significant increase in expression of IL-6 and COX-2 proteins. Results shown as mean ± SD; n = 3, *P < 0.05. D, Effects of IL-17A on COX-2 promoter activity in NP cells. Luciferase activity was assessed to show COX-2 transcription in NP cells after treatment with 50 ng/mL of IL-17A. IL-17A treatment significantly increased COX-2 promoter transcriptional activity. Results shown as mean ± SD; n = 3, *P < 0.05. E, Alcian blue staining quantifying of NP cells treated with 50 ng/mL IL-17A. Optical density of the extracted dye was measured at 670 nm. Results shown as mean ± SD; n = 3, *P < 0.05. F, Real-time PCR analysis of NP cells treated with 50-100 ng/mL IL-6 for 24 hours. The control cells were not treated with IL-6. Treatment with IL-6 led to significantly increased expression of COX-2, MMP-3 and MMP-13 mRNA but had no effect on IL-17A mRNA expression. Results shown as mean ± SD; n = 3, *P < 0.05. G, H, Western blot analysis of NP cells treated with 50 ng/mL IL-6 for 24 hours under hypoxic conditions. IL-6 treatment led to a significant increase in expression of COX-2 proteins. Results shown as mean ± SD; n = 3, *P < 0.05. I, Effects of IL-6 on COX-2 promoter activity in NP cells. Luciferase activity was used to show COX-2 promoter transcription in NP cells after treatment with 50 ng/mL of IL-6, which significantly increased COX-2 promoter transcription activity. Results shown as mean ± SD; n = 3, *P < 0.05 Figure 7F ).These findings demonstrate that the smallmolecule inhibitor, STK, was effective in human NP cells.
| DISCUSSION
In this study, we showed that IL-17A signaling up-regulated IL-6, COX-2, MMP-3 and MMP-13 expression in NP cells under hypoxia.
Furthermore, IL-17A affects the degradation of sulphated glycosaminoglycan, a major extracellular matrix(ECM) component produced by NP cells. In addition, these factors, the elevation of which characterizes IVD diseases, [7] [8] [9] [10] [11] 13 were down-regulated by suppressing IL-17A activation with a neutralizing antibody or smallmolecule inhibitors. These findings are the first to reveal that the IL-17A-IL-17RA interaction is a possible pharmacotherapeutic target and that small-molecule inhibitors of IL-17A-IL-17RA might be utilized for IVD disease therapy.
With respect to the relationship between IL-6 and IL-17A, some
reports have indicated that IL-6 is elevated in response to IL-17A-activated STAT3 in some tumour cells. 39, 40 In our study, IL-6 was increased by IL-17A stimulation and down-regulated when IL-17A signalling was suppressed using an anti-IL-17A antibody or an IL-17A inhibitor. These results suggest that IL-17A may be one of the elements that controls expression of IL-6 in NP cells. Previous studies have reported that IL-6 is secreted by IVD cells in the absence of macrophages 41 and that its expression is elevated in injured IVD cells or herniated discs. 31, 42 Others have shown that IL-6 down-regulates disc matrix formation and promotes disc degeneration 7,9,28,30 and contributes to expression of inflammatory mediators such as TNF-α and PGE2, 28, 30 which lead to neuropathic pain. 29, 43 We found that IL-17A treatment increases IL-6, COX-2, MMP-3 and MMP-13 expression and that IL-6 treatment alone also increases COX-2, MMP-3 and MMP-13 expression. These findings suggest that IL-17A up-regulates IL-6 expression, which in turn induces COX-2 and MMPs in NP cells, contributing to the pathomechanism of disc degeneration and symptoms. Similarly, COX-2
is an important enzyme in PGE-2 biosynthesis in disc cells 8, 44 that plays key roles in the pathophysiology of IVD disease, including lower back pain and sciatica. 7, 8, 17 These studies indicate that COX- The major limitations of this study are described below. We used both rat NP cells and human NP cells, and the notochondal phenotypes are not identical, with the presence of a portion of notochondal cells in adult discs differing in rats and humans. Thus, there is the possibility that the IVD degeneration process in rats is not analogous to that in humans. Our observations using human NP cells included sufficient samples to be statistically analysed; however, it is difficult to collect IVDs from patients of all the same ages in order to have a more controlled patient group. Therefore, concern over age variation of our patients and the effect it has on the degeneration process of IVDs still remains. 
